KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Cited by (183)

Items 101–183 of 183

1. Intra‐heterogeneity in transcription and chemoresistant property of leukemia‐initiating cells in murine Setd2 −/− acute myeloid leukemia
   Jiachun Song, Longting Du, Ping Liu, Fuhui Wang, Bo Zhang, Yinyin Xie, Jing Lu, Yi Jin, Yan Zhou, Gang Lv et al. · 2021 · 癌症：英文版
2. Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia
   Jiabi Qian, Zifeng Li, Kunlin Pei, Ziping Li, Chunjie Li, Muxia Yan, Maoxiang Qian, Yuanbin Song, Hui Zhang, Yingyi He · 2022 · Frontiers in Cell and Developmental Biology
3. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
   Judit Moldvay, József Tı́már · 2024 · Pathology & Oncology Research
4. PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways
   Zi Yu, Qiang Li, Gejun Zhang, Chengcheng Lv, Qingzhuo Dong, Cheng Fu, Chuize Kong, Yu Zeng · 2019 · International Journal of Oncology
5. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
   Sigrid K. Fey, Arafath Kaja Najumudeen, Dale M. Watt, Laura M. Millett, Catriona A. Ford, Kathryn L. Gilroy, Rosalin J. Simpson, Kathy McLay, Rosanna Upstill‐Goddard, David Kuang-Fu Chang et al. · 2024 · Cancer Research
6. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells
   Ningfei An, Saira Saeed Khan, Molly K. Imgruet, Lia Jueng, Sandeep K. Gurbuxani, Megan E. McNerney · 2023 · Oncogene
7. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions
   Marsilius Mues, Laila Karra, Damià Romero–Moya, Anica M. Wandler, Matthew J. Hangauer, Olga Ksionda, Yvonne J. Thus, Marthe F. Lindenbergh, Kevin Shannon, Michael T. McManus et al. · 2019 · Cell Reports
8. Amplification of mutant KRASG12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report
   Fabio Pittella-Silva, Yasutoshi Kimura, Siew‐Kee Low, Yusuke Nakamura, Masayo Motoya · 2021 · Molecular and Clinical Oncology
9. The expressed mutational landscape of microsatellite stable colorectal cancers
   Anita Sveen, Bjarne Johannessen, Ina Andrassy Eilertsen, Bård Ingvald Røsok, Marie Gulla, Peter W. Eide, Jarle Bruun, Kushtrim Kryeziu, Leonardo A. Meza‐Zepeda, Ola Myklebost et al. · 2021 · Genome Medicine
10. KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers
    Gary Joseph Doherty, Emma M. Kerr, Carla P. Martins · 2017 · Trends in Molecular Medicine
11. Brother’s Keeper: Wild-Type Mutant K-Ras Dimers Limit Oncogenesis
    Yi-Jang Lin, Kevin M. Haigis · 2018 · Cell
12. Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias
    Benjamin J. Huang, Anica M. Wandler, Lauren K. Meyer, Monique Dail, Anneleen Daemen, Deepak Sampath, Qing Li, Xinyue Wang, Jasmine C. Y. Wong, Joy Nakitandwe et al. · 2019 · PLoS Genetics
13. Direct KRAS inhibition: progress, challenges, and a glimpse into the future
    Dimitra Grapsa, Konstantinos Syrigos · 2020 · Expert Review of Anticancer Therapy
14. Bioluminescence-based assays for quantifying endogenous protein interactions in live cells
    Andrew L. Niles, Michael Dibble, Thomas Machleidt, Kelli Martino, Matthew Swiatnicki, Elizabeth H. Vu, Marie K. Schwinn · 2025 · Journal of Biological Chemistry
15. Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer
    Rodrigo Gularte‐Mérida, Shaleigh Smith, Anita S. Bowman, Arnaud da Cruz Paula, Walid Khaled Chatila, Craig M. Bielski, Monika Vyas, Laetitia Borsu, Ahmet Zehir, Luciano Gastón Martelotto et al. · 2022 · JCO Precision Oncology
16. TargetingKRAS G12Cmutations in colorectal cancer
    Minghe Zhao, Aiwen Wu · 2022 · Gastroenterology report
17. Ras Variant Biology and Contributions to Human Disease
    Ian A. Prior · 2021 · Methods in molecular biology
18. Approaches to functionally validate candidate genetic variants involved in colorectal cancer predisposition
    Laia Bonjoch, Pilar Mur, Coral Arnau‐Collell, Gardenia Vargas‐Parra, Bahar Shamloo, Sebastià Franch‐Expósito, Marta Pineda, Gabriel Capellá, Batu Erman, Sergi Castellvı́-Bel · 2019 · Molecular Aspects of Medicine
19. Kras in Organoids
    Derek K. Cheng, David Arthur Tuveson · 2018 · Cold Spring Harbor Perspectives in Medicine
20. A disease model resource reveals core principles of tissue-specific cancer evolution
    Sebastian Mueller, Niklas de Andrade Krätzig, Markus Tschurtschenthaler, Miguel G. Silva, Chiara Thordsen, Riccardo Trozzo, Perrine Simon, Frederic Saab, Thorsten Kaltenbacher, Magdalena Żukowska et al. · 2026 · Nature
21. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
    Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, Tânia Capelôa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid et al. · 2024 · Gastric Cancer
22. Nf1 -Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
    Daniela Pucciarelli, Steven P. Angus, Benjamin J. Huang, Chi Zhang, Hiroki J. Nakaoka, Ganesh Krishnamurthi, Sourav Bandyopadhyay, D. Wade Clapp, Kevin Shannon, Gary L. Johnson et al. · 2020 · Molecular Cancer Therapeutics
23. Ten Years of CRISPRing Cancers In Vitro
    Davide Capoferri, Serena Filiberti, Jessica Faletti, Camilla Tavani, Roberto Ronca · 2022 · Cancers
24. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
    Panyu Chen, Benjamin J. Huang, Max Harris, Christopher D. Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C. Kohler, Gideon E. Bollag et al. · 2023 · JCI Insight
25. KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia
    Yibo Wu, Xiaolin Yuan, Xiaoyu Lai, Lizhen Liu, Yue Liang, Luxin Yang, Panpan Zhu, Jimin Shi, Jian Yu, Yanmin Zhao et al. · 2025 · Cancer
26. Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
    Baojun Ren, 高卓维, Kehong Zheng, Yong Yang, Pengfei Su, Qimei Luo, Jing Feng, Luo Zhentao, Yan Geng, Yongle Ju et al. · 2023 · Experimental and Therapeutic Medicine
27. Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
    Elena Lastraioli, Alessandra Bettiol, Jessica Iorio, Elvira Limatola, Daniele Checcacci, Erica Parisi, Cristina Bianchi, Annarosa Arcangeli, Mauro Iannopollo, Francesco Di Costanzo et al. · 2023 · Cells
28. Role of silent mutations in KRAS-mutant tumors
    Jun Guo Lu, Chao Zhou, Feng Pan, Hongyu Liu, Haohua Jiang, Hua Zhong, Baohui Han · 2024 · Chinese Medical Journal
29. RAS: Circuitry and therapeutic targeting
    Gagandeep Singh, Neelam Thakur, Umesh Kumar · 2022 · Cellular Signalling
30. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras
    Anica M. Wandler, Kevin Shannon · 2017 · Cold Spring Harbor Perspectives in Medicine
31. Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review
    Parmar Keshri Nandan, Sivaraman Jayanthi · 2025 · Discover Oncology
32. Doubling Down on Mutant RAS Can MEK or Break Leukemia
    Zuzana Tóthová, Benjamin L. Ebert · 2017 · Cell
33. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL
    Anya L. Levinson, Karensa Tjoa, Benjamin J. Huang, Lauren K. Meyer, Mi‐Ok Kim, Samuel W. Brady, Jinghui Zhang, Kevin Shannon, Anica M. Wandler · 2023 · Blood Advances
34. Transforming Biomarker Development with Exceptional Responders
    Philip Jonsson, Barry S. Taylor · 2017 · Trends in cancer
35. Mutant Allele Imbalance in Cancer
    Craig M. Bielski, Barry S. Taylor · 2020 · Annual Review of Cancer Biology
36. Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic RAS and BRAF variants
    Jasmin B. Post, Nizar Hami, Jeroen O. Lohuis, Marieke van de Ven, Renske de Korte‐Grimmerink, Christina Stangl, Ellen Stelloo, Ingrid Verlaan-Klink, Jacco van Rheenen, Hugo J.G. Snippert · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
37. Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
    Derek K. Cheng, Tobiloba E. Oni, Youngkyu Park, Jennifer S. Thalappillil, Hsiu-Chi Ting, Brinda Alagesan, Nadia V. Prasad, Keith D. Rivera, Darryl Pappin, Linda Van Aelst et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
38. Increased dosage of wild-type KRAS protein drives KRAS -mutant lung tumorigenesis and drug resistance
    Tonči Ivanišević, Wout Magits, Yan Ma, Peihua Zhao, Emiel Van Boxel, Benoit Lechat, Edward C. Stites, Greetje Vande Velde, Raj Nayan Sewduth, Anna A. Sablina · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
39. Targeting Hyperactive Ras Signaling in Pediatric Cancer
    Anya L. Levinson, Kevin Shannon, Benjamin J. Huang · 2024 · Cold Spring Harbor Perspectives in Medicine
40. In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS -Mutant Cancer
    Matthew Decker, Benjamin J. Huang, Timothy B. Ware, Christopher D. Boone, Michelle Tang, Julia Ybarra, Matthew J. Sale, Rony A. Francois, Aishwarya C. Ballapuram, Katrine A. Taran et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
41. Elevated Levels of Mislocalised, Constitutive Ras Signalling Can Drive Quiescence by Uncoupling Cell-Cycle Regulation from Metabolic Homeostasis
    Elliot Piper-Brown, Fiona Dresel, Eman Badr, Campbell W. Gourlay · 2023 · Biomolecules
42. Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution
    Vasiliki Liaki, Blanca Rosas-Pérez, Carmen E. Guerra · 2025 · Cancers
43. Exploiting KRAS-Driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)
    Honglin Jiang, Ryan K. Muir, Ryan L. Gonciarz, Adam B. Olshen, Iwei Yeh, Byron C. Hann, Ning Zhao, Yung-Hua Wang, Spencer C. Behr, Michael J. Evans et al. · 2020 · SSRN Electronic Journal
44. Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth
    Rui Tang, Emily G. Shuldiner, Marcus R. Kelly, Christopher W. Murray, Jess D. Hebert, Laura Andrejka, Min K. Tsai, Nicholas W. Hughes, Mitchell I. Parker, Hongchen Cai et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
45. The rise of RAS: how gradual oncogene activation shapes the OIS spectrum
    Haoran Zhu, Adelyne Sue Li Chan, Masashi Narita · 2025 · Genes & Development
46. The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
    Irene Ballesteros-González, Ivan Hernández-Navas, Oksana Brehey, Carmen G. Lechuga, Marina Salmón, Morena Scotece, Ricardo Velasco-Vicente, Alejandra A. Flores-Gómez, Antonio Cebriá, Lucía Simón-Carrasco et al. · 2025 · EMBO Molecular Medicine
47. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations
    Kwangrok Jung, Jong-Chan Lee, Jin-Ho Kim, Hee Young Na, Jae Hyeong Kim, Yuna Youn, Namyoung Para, Jaihwan Kim, Jin‐Hyeok Hwang · 2025 · Cancer Letters
48. Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides
    Jayati Mondal, D. Lam, Termika O. Alcindor, Mary E. Gerritsen, Tilmann M. Brotz, Jodi Kennedy, Bruce Rehlaender, Arthur J. Ross, Daniel E. Levy, Christopher A. Bonagura et al. · 2026 · International Journal of Molecular Sciences
49. Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
    Joseph Tintelnot, Sina Metz, Marie Trentmann, Anna Oberle, Lisa von Wenserski, Christoph Schultheiß, Friederike Braig, Malte Kriegs, Boris Fehse, Kristoffer Riecken et al. · 2020 · Frontiers in Oncology
50. Exonic variants undergoing allele-specific selection in cancers
    Qiyuan Li, Yuanyuan Zeng, Janet Wang, Hongkun Fang, Jintao Guo, Liying Yu, Taoling Zhong, Chaoqun Xu, Matthew L. Freedman, Thomas LaFramboise · 2021 · BMC Medical Genomics
51. Danger zone
    Zohra Butt, Ian A. Prior · 2021 · eLife
52. Fitness depends on KRAS imbalance
    Diana Romero · 2017 · Nature Reviews Clinical Oncology
53. PIK3CA in Kras G12D /Trp53 R172H Tumor Cells Promotes Immune Evasion by Limiting Infiltration of T Cells in a Model of Pancreatic Cancer
    Nithya Sivaram, Patrick A. McLaughlin, Han V. Han, Oleksi Petrenko, Ya-Ping Jiang, Lisa M. Ballou, Kien Pham, Chen Liu, Adrianus W. M. van der Velden, Richard Z. Lin · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
54. Biopsy of palliative lesions following radiotherapy
    Shiro Fujita, Katsuhiro Masago, Yasushi Yatabe · 2019 · BJR|Open
55. Translational research of combined anticancer therapies targeting the MAPK pathway
    Sanne C.F.A. Huijberts · 2021 · Utrecht University Repository (Utrecht University)
56. Faculty Opinions recommendation of MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.
    Wafik S. El‐Deiry, Liz Hernandez Borerro · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
57. Evaluation of K-Ras4B dimer interfaces and the role of Raf effectors
    Alexios Chatzigoulas, Ioannis Andreadelis, Stefan Doerr, Christos Lamprakis, Anastasia Theodoropoulou, John I. Manchester, Camilo Velez‐Vega, José S. Duca, Zoe Cournia · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
58. Data from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
    Daniela Pucciarelli, Steven P. Angus, Benjamin J. Huang, Chi Zhang, Hiroki J. Nakaoka, Ganesh Krishnamurthi, Sourav Bandyopadhyay, D. Wade Clapp, Kevin Shannon, Gary L. Johnson et al. · 2023
59. Data from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
    Daniela Pucciarelli, Steven P. Angus, Benjamin J. Huang, Chi Zhang, Hiroki J. Nakaoka, Ganesh Krishnamurthi, Sourav Bandyopadhyay, D. Wade Clapp, Kevin Shannon, Gary L. Johnson et al. · 2023
60. Integrative study of whole exome variation and expression in gingivo-buccal oral squamous cell carcinoma revealed alteration in TLR-activated MAP-Kinase signalling
    Richa Singh, Esita Chattopadhyay, Anindita Ray, Roshni Roy, Nidhan K. Biswas, Sandip Ghose, Bidyut Roy · 2023 · Human Gene
61. Genotype-Phenotype Correlation in Noonan Syndrome – Focus on LZTR1 and its Substrates
    Alexandra Viktoria Busley · 2023
62. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo
    Arafath Kaja Najumudeen, Sigrid K. Fey, Laura M. Millett, Catriona A. Ford, Kathryn L. Gilroy, Nuray Gündüz, Rachel A. Ridgway, Eve Anderson, Douglas Strathdee, William Andrew Clark et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
63. Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity
    Sigrid K. Fey, Arafath Kaja Najumudeen, Catriona A. Ford, Kathryn L. Gilroy, Rosanna Upstill‐Goddard, David Kuang-Fu Chang, William Clark, Colin Nixon, Simon T. Barry, Jennifer P. Morton et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
64. Conditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling
    Soo‐Yeon Lee, Ki‐Young Lee · 2024 · Angewandte Chemie
65. Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor
    Adrian L. Gill, Mathew A. Marx · 2024 · Elsevier eBooks
66. Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis
    Abderaouf Hamza, Pierre Gestraud, Maryam Karimi, Alicia Tran-Dien, Laurène Syx, Sophie Vacher, Quentin Peretti, Ludovic Lacroix, Valéry Attignon, Isabelle Soubeyran et al. · 2025 · British Journal of Cancer
67. Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
    Benjamin J. Huang, Jeevitha D’Souza, Alexa Rane Batingana, Max Harris, Xinyue Wang, Eugene Hwang, Anica M. Wandler, Michael R. Burgess, Qing Li, Soheil Meshinchi et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
68. Additional file 1 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
69. Additional file 8 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
70. Additional file 9 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
71. Additional file 3 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Hongkun Fang, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
72. Additional file 6 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
73. Additional file 5 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
74. Additional file 7 of Exonic variants undergoing allele-specific selection in cancers
    Li, Qiyuan, Zeng, Yuanyuan, Wang, Janet, Fang, Hongkun, Jintao Guo, Yu, Liying, Zhong, Taoling, Xu, Chaoqun, Matthew L. Freedman, Thomas LaFramboise · 2021 · Figshare
75. Online tutorial on survival analysis for biomarker discovery
    Jaka Kokošar, Ela Praznik, Martin Špendl, Nancy P. Moreno, Alana D. Newell, Gad Shaulsky, Blaž Zupan · 2026 · PLoS Computational Biology
76. Caractérisation moléculaire et étude des conséquences fonctionnelles des mutations somatiques du gène NF1 dans les carcinomes bronchiques non à petites cellules
    Camille Tlemsani · 2018 · theses.fr (ABES)
77. Control of antitumor immunity by the SQSTM1 dependent signaling
    Nathalie Yazbeck · 2018
78. Single cell multi-OMICS analysis of Treg biology in cancer
    Wilfrid Richer · 2021 · theses.fr (ABES)
79. MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
    Sergio de Hita Román · 2023 · theses.fr (ABES)
80. Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response
    Alice T. Browne, Chris McCann, William J. McDaid, Nikita Lewis, Sandhya Sridhar, Gary Joseph Doherty, Deborah Y. Moss, Matilda Downs, Stephen Marry, A.R. Phillips et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
81. Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity
    John N. Colgan, Jack H. Peplinski, Yi-Cheng Wang, Danielle C. Kirkey, Logan K. Wallace, Yuan Feng, Li Fan, Patrick Connerty, Rhonda E. Ries, Adam J. Lamble et al. · 2026 · Blood Advances
82. Discovery of hydrazone derivatives as novel STAT3 antagonists against pancreatic and colorectal cancers
    Hsin-Yu Yang, Min-Hua Chiu, Po‐Chang Shih · 2026 · Bioorganic Chemistry
83. Mutational Landscapes in Core Binding Factor Acute Myeloid Leukaemia: A Single-Centre Study from Eastern India
    Chumki Bhattacharjee, Prakhar Gupta, Asish Rath, Kallol Saha, Saheli Banerjee, Debajani Nathi, Mayur Parihar, Jeevan Kumar, Reena Nair, Arijit Nag et al. · 2026 · Indian Journal of Hematology and Blood Transfusion